Publication | Closed Access
Brief Report: A phase IIa, randomized, double‐blind, placebo‐controlled trial of apilimod mesylate, an interleukin‐12/interleukin‐23 inhibitor, in patients with rheumatoid arthritis
82
Citations
15
References
2011
Year
Our results do not support the notion that IL-12/IL-23 inhibition by apilimod is able to induce robust clinical improvement in RA.
| Year | Citations | |
|---|---|---|
Page 1
Page 1